Cameron Durrant, Humanigen CEO (Columbia University Technology Ventures via YouTube)
With failed NIH Covid-19 study, Humanigen CEO points to competitors' flops before FDA nods
Humanigen is going back to the drawing board for its antibody meant to thwart so-called cytokine storms as the drug has failed an NIH Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
